ADDERALL 15
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADDERALL 15 (ADDERALL 15).
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
| Metabolism | Amphetamine is metabolized primarily by hepatic CYP2D6 and to a lesser extent by CYP2C19 and CYP2C9, with some minor pathways involving dopamine beta-hydroxylase. |
| Excretion | Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%). |
| Half-life | Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID. |
| Protein binding | ~16-20%; primarily binds to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 3.0-4.5 L/kg (range 2.6-5.6); indicates extensive tissue distribution, including brain, with accumulation in kidneys and liver. |
| Bioavailability | Oral: ~76% (range 64-95%) for mixed amphetamine salts; bioavailability reduced by acidic gastric pH and increased with food (Tmax delayed but AUC unchanged). |
| Onset of Action | Oral: 30-60 min for CNS stimulation; peak plasma concentration at 3 h with mixed amphetamine salts. |
| Duration of Action | Oral: 4-6 h for immediate-release; extended-release (ADDERALL XR) provides 8-12 h. Clinical note: duration varies with individual metabolism and tolerance. |
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | Weight-based: <50 kg: 2.5-5 mg once daily; 50-100 kg: 5-10 mg once daily; >100 kg: adult dosing. |
| Geriatric use | Start at 2.5-5 mg once daily; increase slowly due to increased sensitivity and cardiovascular risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ADDERALL 15 (ADDERALL 15).
| Breastfeeding | Present in breast milk; M/P ratio approximately 2.5-7.5. Potential for infant stimulation, insomnia, reduced weight gain. Caution recommended; consider delaying breastfeeding until 1-2 hours after dose. |
| Teratogenic Risk | First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/third trimesters: Risk of fetal growth restriction, preterm delivery, neonatal withdrawal (irritability, feeding problems), and persistent pulmonary hypertension. |
■ FDA Black Box Warning
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout therapy.
| Serious Effects |
["Hypersensitivity to amphetamine or other components","Concurrent use or within 14 days of MAOIs (risk of hypertensive crisis)","Glaucoma","Hyperthyroidism","Agitated states","History of drug abuse","Cardiovascular disease (symptomatic, moderate to severe hypertension, advanced arteriosclerosis, structural cardiac abnormalities)"]
| Precautions | ["Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems","Blood pressure and heart rate increases","Psychiatric adverse events (exacerbation of pre-existing psychosis, manic episodes, aggressive behavior)","Seizures (may lower seizure threshold)","Peripheral vasculopathy including Raynaud's phenomenon","Serotonin syndrome risk, especially with concomitant serotonergic drugs","Long-term growth suppression in children"] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, heart rate, weight, and symptoms of toxicity. Fetal: serial growth ultrasounds, amniotic fluid assessment, and periodic fetal heart rate monitoring. Neonatal: Observe for withdrawal signs and growth parameters. |
| Fertility Effects | May impair fertility in females via inhibition of ovulation at high doses (based on animal data). Human data limited; reversible upon discontinuation. Use with caution in women attempting conception. |
| Avoid high-fat meals close to dosing as they may delay absorption. Acidic foods (e.g., citrus, cola, vitamin C) can decrease absorption; take with non-acidic fluids. Avoid alcohol and caffeine-containing products. |
| Clinical Pearls | Adderall 15 mg (amphetamine/dextroamphetamine) is an immediate-release formulation; onset 30-60 min, duration 4-6 hours. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Consider drug holidays to assess need and reduce tolerance. Do not use with MAOIs or within 14 days of MAOI therapy. Risk of abuse and dependence; screen for substance use history. Use with caution in patients with pre-existing cardiovascular disease or psychiatric disorders. |
| Patient Advice | Take exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Take the first dose in the morning; if prescribed a second dose, take it by early afternoon to avoid sleep problems. · Swallow tablet whole; do not crush or chew. · Avoid alcohol and caffeine; may increase side effects like nervousness and rapid heartbeat. · Report chest pain, palpitations, shortness of breath, or fainting immediately. · Inform your doctor of all medications, including over-the-counter and herbal products, especially antidepressants. · May cause weight loss; monitor growth in children. · Can impair ability to drive or operate machinery until you know how it affects you. · Store at room temperature away from moisture and heat. · Do not abruptly stop; taper under medical supervision to avoid withdrawal. |